Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325615 | 1.00 | TACR3 (0.44) | TACR3ATMPIK3C3TACR1CYP2C9 | |
| SCHEMBL17541996 | 0.84 | TACR3 (0.43) | TACR3CYP2C9CYP2C19MAPK14 | |
| SCHEMBL17542208 | 0.84 | TACR3 (0.43) | TACR3CYP2C9CYP2C19MAPK14 | |
| SCHEMBL18862948 | 0.84 | TACR3 (0.43) | TACR3CYP2C9CYP2C19MAPK14 | |
| SCHEMBL17542235 | 0.84 | TACR3 (0.43) | TACR3CYP2C9CYP2C19MAPK14 | |
| SCHEMBL17541969 | 0.84 | TACR3 (0.43) | TACR3CYP2C9CYP2C19MAPK14 | |
| SCHEMBL21461278 | 0.84 | TACR1 (0.40) | TACR3TACR1CYP2C9CYP2C19MAPK14 | |
| SCHEMBL29997914 | 0.83 | SMN1; SMN2 (0.51) | CYP2C19MEN1KMT2A | |
| SCHEMBL23459409 | 0.83 | GBA1 (0.43) | TACR3ATMCYP2C9CYP2C19MAPK14 | |
| SCHEMBL6326488 | 0.83 | GBA1 (0.43) | TACR3ATMCYP2C9CYP2C19MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | TACR3 4161/4885ATM 4737/4885PIK3C3 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.